Comments – Part of the EMA’s continued commitment to RWE in support of
medicinal product utilisation. When you see regulators investing in
infrastructure like this, you know they are serious about the promises made
about use of RWE.
CONTEXT: Data Analytics, RWR & Regulators, *Panalgo, **Instant Health Data
IMPACT: Ability to produce timely evidence-based insights
READ TIME: 2 mins
*1. “Six months after rebranding from BHE, Panalgo has won a contract to
supply the European Medicines Agency (EMA) with its IHD data analytics
platform, pledging to streamline its public health efforts.” *
*2. “IHD – or Instant Health Data – will be used by the EMA to carry out
data analyses and examine medicinal product utilisation, answer questions
about safety and efficacy, and understand how treatments perform in
real-world settings, said the Boston, US-based company.” *
*3. ““Our company is strongly aligned with the EMA’s public health goals,
for which timely evidence-based insights are of particular importance,
especially during this COVID-19 pandemic,” commented the US company’s CEO
Joseph Menzin.” *
*4. “The new agreement with the EMA adds a new dimension to Panalgo’s data
analytics business, as most of its clients have so far been life science
companies and research organisations.” *
*5. “The company says IHD passed a rigorous assessment by the EMA – in
competition with software from other providers – and will support
decision-making at the population level, including therapy risk/benefit and
life cycle analyses that can be used in public health planning.” *
Source URL:
https://pharmaphorum.com/news/ema-will-use-panalgo-software-for-real-world-data-analytics/